

REMARKS

Claims 1 and 3-48 are pending in the present application. Claims 1, 3, 4, 20, 33 and 48 have been indicated as being allowable. The Action has rejected claims 5-19, 21-32 and 34-47.

In view of the above amendments and following remarks, Applicants request reconsideration of the last Action.

Rejections under 35 U.S.C §112

Claims 5-19, 21-32 and 34-47 have been rejected under 35 U.S.C §112 first paragraph as failing to comply with the requirement for enablement.

While not necessarily agreeing with what has been asserted by the Office in this rejection, and in order to move the other pending claims forward to allowance, claims 5-19, 21-32 and 34-47 have been cancelled by the amendment herewith. It is believed that this renders the rejection moot. Entry of this amendment and withdrawal of the rejection is respectfully requested.

The Applicants reserve the right to pursue the cancelled claims in a continuing application.

Conclusion

Applicants gratefully thank the Office for the consideration given to this application.

The Commissioner is hereby authorized to charge the fee required for a three month extension of time for response, to June 29, 2009, and any additional fees that may be needed to Deposit Account No. **18-1982** in the name of Aventis Pharmaceuticals Inc.

Respectfully submitted,

/James W. Bolcsak, Reg. No. 39912/

James W. Bolcsak, Reg. No.: 39,912
Attorney for Applicants
June 27, 2009

sanofi-aventis U.S.
US Patent Department
1041 Route #202-206
Bridgewater, NJ 08807-0800
Telephone (908) 231-5922
Telefax (908) 231-2626
DEAV2002/0094 US CNT